Your browser is no longer supported. Please, upgrade your browser.
CNST Constellation Pharmaceuticals, Inc. monthly Stock Chart
CNST [NASD]
Constellation Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.50 Insider Own12.90% Shs Outstand41.77M Perf Week1.90%
Market Cap1.38B Forward P/E- EPS next Y-2.95 Insider Trans-1.30% Shs Float29.53M Perf Month-15.14%
Income-91.60M PEG- EPS next Q-0.64 Inst Own83.40% Short Float14.19% Perf Quarter-13.55%
Sales- P/S- EPS this Y11.70% Inst Trans1.32% Short Ratio6.38 Perf Half Y-23.89%
Book/sh7.55 P/B3.91 EPS next Y-10.10% ROA-36.90% Target Price- Perf Year199.80%
Cash/sh7.66 P/C3.85 EPS next 5Y- ROE-47.70% 52W Range6.01 - 59.49 Perf YTD-37.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.36% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low391.35% ATR2.53
Employees106 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)36.33 Volatility5.95% 9.35%
OptionableYes Debt/Eq0.00 EPS Q/Q19.10% Profit Margin- Rel Volume0.75 Prev Close29.13
ShortableYes LT Debt/Eq0.09 Earnings- Payout- Avg Volume656.78K Price29.53
Recom1.90 SMA20-5.17% SMA50-18.09% SMA200-8.89% Volume493,477 Change1.37%
Jun-24-20Initiated JMP Securities Mkt Perform $36
May-07-20Reiterated H.C. Wainwright Buy $50 → $75
Feb-13-20Initiated SunTrust Buy $50
Feb-07-20Initiated Cowen Outperform
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $43 → $42
Sep-04-19Initiated RBC Capital Mkts Outperform $20
Jan-29-19Initiated Robert W. Baird Outperform $17
Dec-20-18Initiated H.C. Wainwright Buy $18
Dec-20-18Initiated H.C. Wainwright Buy
Aug-13-18Initiated JP Morgan Overweight $17
Jul-06-20 12:13PM  
Jun-22-20 04:35PM  
Jun-16-20 08:27PM  
Jun-15-20 04:01PM  
09:47AM  
Jun-12-20 02:30AM  
Jun-10-20 11:30AM  
Jun-08-20 08:00AM  
May-29-20 09:00AM  
May-28-20 12:00PM  
May-25-20 12:00PM  
May-14-20 09:24AM  
08:00AM  
May-09-20 08:22PM  
May-06-20 03:32PM  
07:00AM  
May-05-20 02:06PM  
Apr-28-20 09:00AM  
Apr-24-20 12:00PM  
Apr-06-20 07:00AM  
Mar-24-20 08:58AM  
Mar-16-20 12:00PM  
Mar-10-20 04:12PM  
03:00PM  
Mar-06-20 01:00PM  
Feb-26-20 09:00AM  
Feb-19-20 10:35AM  
Jan-09-20 02:50PM  
Jan-06-20 12:34PM  
Dec-27-19 02:19PM  
Dec-16-19 06:00AM  
Dec-13-19 04:05PM  
Dec-10-19 09:05PM  
Dec-09-19 04:18PM  
10:00AM  
Dec-02-19 11:00AM  
Nov-29-19 12:15PM  
Nov-25-19 12:43PM  
Nov-13-19 09:00AM  
Nov-07-19 10:34PM  
Nov-06-19 11:35AM  
09:00AM  
06:48AM  
Oct-31-19 10:00AM  
Oct-14-19 08:06AM  
Oct-10-19 07:00AM  
Oct-04-19 08:52AM  
Oct-01-19 07:00AM  
Sep-26-19 12:00PM  
Sep-24-19 07:00AM  
Sep-23-19 07:17PM  
Aug-21-19 09:00AM  
Aug-07-19 04:05PM  
Jul-25-19 01:39PM  
Jun-13-19 02:57PM  
Jun-12-19 09:00AM  
Jun-03-19 09:00AM  
May-31-19 11:00AM  
May-23-19 10:28AM  
May-20-19 07:00AM  
May-16-19 09:00AM  
May-08-19 04:15PM  
Apr-19-19 08:00AM  
Apr-10-19 07:01PM  
Mar-14-19 05:24PM  
Mar-06-19 02:35PM  
Mar-04-19 07:00AM  
Feb-25-19 09:02AM  
Feb-22-19 01:24PM  
Feb-20-19 07:00AM  
Feb-12-19 08:52AM  
Feb-08-19 10:05AM  
10:03AM  
Feb-05-19 09:17AM  
Feb-04-19 09:50AM  
Jan-03-19 07:00AM  
Dec-20-18 01:34PM  
Dec-11-18 08:22AM  
Dec-10-18 04:49PM  
Nov-29-18 02:00PM  
09:22AM  
Nov-21-18 07:20AM  
Nov-15-18 07:00AM  
Nov-08-18 04:30PM  
Nov-02-18 01:08PM  
Nov-01-18 07:00AM  
Oct-10-18 04:30PM  
Sep-28-18 02:48PM  
Sep-12-18 09:00AM  
Sep-04-18 06:30AM  
Aug-14-18 04:15PM  
Aug-13-18 11:58AM  
Jul-19-18 11:47AM  
11:31AM  
07:56AM  
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reeve EmmaChief Financial OfficerJun 08Option Exercise7.605894,476589Jun 10 06:50 PM
Reeve EmmaChief Financial OfficerJun 08Sale37.5558922,1180Jun 10 06:50 PM
Raythatha JigarSee RemarksMay 12Option Exercise5.519,20950,74224,170May 13 06:25 PM
GOLDSMITH MARK ADirectorMay 12Option Exercise4.124,22517,399147,288May 13 06:29 PM
Senderowicz AdrianChief Medical OfficerMay 12Option Exercise5.519,35751,55725,241May 13 06:30 PM
Audia James EDirectorMay 12Sale50.106,100305,62225,434May 13 06:30 PM
Senderowicz AdrianChief Medical OfficerMay 12Sale50.189,357469,48815,884May 13 06:30 PM
GOLDSMITH MARK ADirectorMay 12Sale50.054,225211,474143,063May 13 06:29 PM
Raythatha JigarSee RemarksMay 12Sale50.179,209461,98114,961May 13 06:25 PM
Reeve EmmaChief Financial OfficerMay 11Option Exercise8.9216,062143,26916,062May 12 09:41 PM
Raythatha JigarSee RemarksMay 11Option Exercise5.512614314,987May 13 06:25 PM
GOLDSMITH MARK ADirectorMay 11Option Exercise1.55100155143,163May 13 06:29 PM
GOLDSMITH MARK ADirectorMay 11Sale50.001005,000143,063May 13 06:29 PM
Raythatha JigarSee RemarksMay 11Sale50.00261,30014,961May 13 06:25 PM
Reeve EmmaChief Financial OfficerMay 11Sale49.5316,062795,6230May 12 09:41 PM
Reeve EmmaChief Financial OfficerMay 08Option Exercise9.8512,741125,46712,741May 12 09:41 PM
Reeve EmmaChief Financial OfficerMay 08Sale49.5312,741631,0550May 12 09:41 PM
GOLDSMITH MARK ADirectorMay 06Option Exercise4.2611,46348,825154,526May 07 04:25 PM
Valentine KarenSee RemarksMay 06Option Exercise10.9612,566137,74912,566May 07 04:34 PM
Trojer PatrickChief Scientific OfficerMay 06Option Exercise7.0410,00070,38510,000May 07 04:39 PM
Trojer PatrickChief Scientific OfficerMay 06Sale45.1610,000451,5530May 07 04:39 PM
Valentine KarenSee RemarksMay 06Sale40.1012,566503,8970May 07 04:34 PM
Audia James EDirectorMay 06Sale45.157,500338,60031,534May 07 04:28 PM
GOLDSMITH MARK ADirectorMay 06Sale45.0611,463516,545143,063May 07 04:25 PM
GOLDSMITH MARK ADirectorMay 05Option Exercise3.503,14511,006146,208May 07 04:25 PM
Valentine KarenSee RemarksMay 05Option Exercise11.504,74454,5564,744May 07 04:34 PM
Valentine KarenSee RemarksMay 05Sale40.014,744189,8170May 07 04:34 PM
GOLDSMITH MARK ADirectorMay 05Sale40.013,145125,824143,063May 07 04:25 PM
Valentine KarenSee RemarksApr 27Option Exercise11.504004,600400Apr 29 08:03 PM
GOLDSMITH MARK ADirectorApr 27Option Exercise1.55400620143,463Apr 29 08:20 PM
GOLDSMITH MARK ADirectorApr 27Sale40.1240016,049143,063Apr 29 08:20 PM
Valentine KarenSee RemarksApr 27Sale40.1340016,0520Apr 29 08:03 PM
Valentine KarenSee RemarksApr 20Option Exercise11.507899,074789Apr 22 08:17 PM
Valentine KarenSee RemarksApr 20Sale33.6578926,5500Apr 22 08:17 PM
Reeve EmmaChief Financial OfficerApr 17Option Exercise6.617605,024760Apr 20 05:53 PM
Valentine KarenSee RemarksApr 17Option Exercise11.502,30026,4502,300Apr 20 05:52 PM
Valentine KarenSee RemarksApr 17Sale35.192,30080,9390Apr 20 05:52 PM
Reeve EmmaChief Financial OfficerApr 17Sale35.2976026,8200Apr 20 05:53 PM
Valentine KarenSee RemarksApr 16Option Exercise11.502,99834,4772,998Apr 20 05:52 PM
Valentine KarenSee RemarksApr 16Sale33.572,998100,6370Apr 20 05:52 PM
Reeve EmmaChief Financial OfficerApr 14Option Exercise8.761,22510,7311,225Apr 16 02:31 PM
Reeve EmmaChief Financial OfficerApr 14Sale35.201,22543,1230Apr 16 02:31 PM
Valentine KarenSee RemarksApr 09Option Exercise8.766355,563635Apr 13 04:56 PM
Reeve EmmaChief Financial OfficerApr 09Option Exercise7.787005,449589Apr 13 04:55 PM
Reeve EmmaChief Financial OfficerApr 09Sale35.0270024,5130Apr 13 04:55 PM
Valentine KarenSee RemarksApr 09Sale35.0263522,2360Apr 13 04:56 PM
COLUMN GROUP L P10% OwnerMar 20Buy23.155,539128,2286,051,376Mar 23 06:59 PM
COLUMN GROUP L P10% OwnerMar 20Buy23.155,539128,2286,051,376Mar 23 06:57 PM
COLUMN GROUP L P10% OwnerMar 19Buy22.3836,135808,7016,045,837Mar 23 06:59 PM
COLUMN GROUP L P10% OwnerMar 19Buy22.3836,135808,7016,045,837Mar 23 06:57 PM
Valentine KarenSee RemarksMar 09Option Exercise8.766175,405617Mar 11 04:11 PM
Valentine KarenSee RemarksMar 09Sale32.0361719,7630Mar 11 04:11 PM
Reeve EmmaChief Financial OfficerFeb 13Option Exercise8.045,52144,3895,521Feb 14 05:09 PM
Valentine KarenSee RemarksFeb 13Option Exercise10.334,47346,2174,473Feb 14 05:09 PM
Valentine KarenSee RemarksFeb 13Sale35.074,473156,8590Feb 14 05:09 PM
Reeve EmmaChief Financial OfficerFeb 13Sale35.065,521193,5390Feb 14 05:09 PM
Reeve EmmaChief Financial OfficerFeb 12Option Exercise8.041,1038,8681,103Feb 14 05:09 PM
Valentine KarenSee RemarksFeb 12Option Exercise11.501,50017,2501,500Feb 14 05:09 PM
Valentine KarenSee RemarksFeb 12Sale35.021,50052,5270Feb 14 05:09 PM
Reeve EmmaChief Financial OfficerFeb 12Sale35.021,10338,6240Feb 14 05:09 PM
Reeve EmmaChief Financial OfficerFeb 11Option Exercise7.678,64266,3087,212Feb 12 05:36 PM
Valentine KarenSee RemarksFeb 11Option Exercise11.508,55098,3258,550Feb 12 05:36 PM
Valentine KarenSee RemarksFeb 11Sale35.038,550299,5070Feb 12 05:36 PM
Reeve EmmaChief Financial OfficerFeb 11Sale35.048,642302,8160Feb 12 05:36 PM
Reeve EmmaChief Financial OfficerFeb 10Option Exercise7.602001,520200Feb 12 05:36 PM
Valentine KarenSee RemarksFeb 10Option Exercise11.5014,096162,10414,096Feb 12 05:36 PM
Valentine KarenSee RemarksFeb 10Sale33.5114,096472,3570Feb 12 05:36 PM
Reeve EmmaChief Financial OfficerFeb 10Sale35.002007,0000Feb 12 05:36 PM
EVNIN ANTHONY BDirectorDec 13Buy34.50400,00013,800,0005,742,765Dec 16 05:57 PM
Venrock Healthcare Capital Par10% OwnerDec 13Buy34.50400,00013,800,0004,016,873Dec 16 05:56 PM